The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Bondenza     [1-hydroxy-3-(methyl-pentyl- amino)-1...

Synonyms: Bondronat, Bonviva, Boniva, Ibandronate, CHEMBL997, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Ibandronic Acid

  • Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2 [1].
  • To inhibit bone resorption, a potent bisphosphonate, ibandronate (4 microg/mouse) was daily administered subcutaneously [1].
  • We determined the effects of the potent bisphosphonate ibandronate in a murine model of human myeloma bone disease [2].
  • In contrast, ibandronate failed to inhibit MDA-231 tumor formation with no effects on apoptosis in MDA-231 breast cancer cells in the orthotopic mammary fat pads [3].
  • PURPOSE: To evaluate the hypocalcemic effect and safety of three different doses of the bisphosphonate ibandronate in tumor-associated hypercalcemia, and to identify factors predicting response [4].

Psychiatry related information on Ibandronic Acid


High impact information on Ibandronic Acid

  • There was no significant effect of ibandronate on total myeloma cell burden, as assessed by morphometric measurements of myeloma cells in the bone marrow, liver, and spleen, or by measurement of serum IgG2b levels [2].
  • However, ibandronate did not prevent the mice from developing hindlimb paralysis and did not produce a detectable effect on survival [2].
  • Consistent with this notion, inhibition of bone resorption by the bisphosphonate ibandronate reduced COX-2 expression in MDA-MB-231 cells in bone [6].
  • This open-label pilot study investigated the effects of short-term intensive treatment with intravenous (i.v.) ibandronate on opioid-resistant bone pain in patients with skeletal metastases [7].
  • Ibandronate was well tolerated, with no evidence of renal toxicity [7].

Chemical compound and disease context of Ibandronic Acid


Biological context of Ibandronic Acid


Anatomical context of Ibandronic Acid


Associations of Ibandronic Acid with other chemical compounds


Gene context of Ibandronic Acid


Analytical, diagnostic and therapeutic context of Ibandronic Acid


  1. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. Yoneda, T., Sasaki, A., Dunstan, C., Williams, P.J., Bauss, F., De Clerck, Y.A., Mundy, G.R. J. Clin. Invest. (1997) [Pubmed]
  2. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Dallas, S.L., Garrett, I.R., Oyajobi, B.O., Dallas, M.R., Boyce, B.F., Bauss, F., Radl, J., Mundy, G.R. Blood (1999) [Pubmed]
  3. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Hiraga, T., Williams, P.J., Mundy, G.R., Yoneda, T. Cancer Res. (2001) [Pubmed]
  4. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. Pecherstorfer, M., Herrmann, Z., Body, J.J., Manegold, C., Degardin, M., Clemens, M.R., Thürlimann, B., Tubiana-Hulin, M., Steinhauer, E.U., van Eijkeren, M., Huss, H.J., Thiébaud, D. J. Clin. Oncol. (1996) [Pubmed]
  5. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. Miller, P.D., McClung, M.R., Macovei, L., Stakkestad, J.A., Luckey, M., Bonvoisin, B., Reginster, J.Y., Recker, R.R., Hughes, C., Lewiecki, E.M., Felsenberg, D., Delmas, P.D., Kendler, D.L., Bolognese, M.A., Mairon, N., Cooper, C. J. Bone Miner. Res. (2005) [Pubmed]
  6. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Hiraga, T., Myoui, A., Choi, M.E., Yoshikawa, H., Yoneda, T. Cancer Res. (2006) [Pubmed]
  7. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. Mancini, I., Dumon, J.C., Body, J.J. J. Clin. Oncol. (2004) [Pubmed]
  8. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. Rizzoli, R., Thiébaud, D., Bundred, N., Pecherstorfer, M., Herrmann, Z., Huss, H.J., Rückert, F., Manegold, C., Tubiana-Hulin, M., Steinhauer, E.U., Degardin, M., Thürlimann, B., Clemens, M.R., Eghbali, H., Body, J.J. J. Clin. Endocrinol. Metab. (1999) [Pubmed]
  9. Bisphosphonates: from the laboratory to the clinic and back again. Russell, R.G., Rogers, M.J. Bone (1999) [Pubmed]
  10. Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. von Tirpitz, C., Klaus, J., Steinkamp, M., Hofbauer, L.C., Kratzer, W., Mason, R., Boehm, B.O., Adler, G., Reinshagen, M. Aliment. Pharmacol. Ther. (2003) [Pubmed]
  11. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. De Cock, E., Hutton, J., Canney, P., Body, J.J., Barrett-Lee, P., Neary, M.P., Lewis, G. Clinical therapeutics. (2005) [Pubmed]
  12. Effect of ibandronate on bone loss and renal function after kidney transplantation. Grotz, W., Nagel, C., Poeschel, D., Cybulla, M., Petersen, K.G., Uhl, M., Strey, C., Kirste, G., Olschewski, M., Reichelt, A., Rump, L.C. J. Am. Soc. Nephrol. (2001) [Pubmed]
  13. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. Frith, J.C., Rogers, M.J. J. Bone Miner. Res. (2003) [Pubmed]
  14. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Luckman, S.P., Hughes, D.E., Coxon, F.P., Graham, R., Russell, G., Rogers, M.J. J. Bone Miner. Res. (1998) [Pubmed]
  15. Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. Pecherstorfer, M., Jilch, R., Sauty, A., Horn, E., Keck, A.V., Zimmer-Roth, I., Thiebaud, D. J. Bone Miner. Res. (2000) [Pubmed]
  16. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Fournier, P., Boissier, S., Filleur, S., Guglielmi, J., Cabon, F., Colombel, M., Clézardin, P. Cancer Res. (2002) [Pubmed]
  17. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. McClung, M.R., Wasnich, R.D., Recker, R., Cauley, J.A., Chesnut, C.H., Ensrud, K.E., Burdeska, A., Mills, T. J. Bone Miner. Res. (2004) [Pubmed]
  18. Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Lalla, S., Hothorn, L.A., Haag, N., Bader, R., Bauss, F. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. (1998) [Pubmed]
  19. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. van beek, E., Löwik, C., van der Pluijm, G., Papapoulos, S. J. Bone Miner. Res. (1999) [Pubmed]
  20. Ibandronate: pharmacology and preclinical studies. Russell, R.G. Bone (2006) [Pubmed]
  21. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Bauss, F., Russell, R.G. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. (2004) [Pubmed]
  22. Pro-inflammatory effects of the aminobisphosphonate ibandronate in vitro and in vivo. Richards, P.J., Amos, N., Williams, A.S., Williams, B.D. Rheumatology (Oxford, England) (1999) [Pubmed]
  23. The bisphosphonate ibandronate stimulates reverse cholesterol transport out of monocytoid cells by enhanced ABCA1 transcription. Strobach, D., Lorenz, R.L. Biochem. Biophys. Res. Commun. (2003) [Pubmed]
  24. Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Adwan, H., Bäuerle, T., Najajreh, Y., Elazer, V., Golomb, G., Berger, M.R. Int. J. Oncol. (2004) [Pubmed]
  25. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. Terpos, E., Viniou, N., de la Fuente, J., Meletis, J., Voskaridou, E., Karkantaris, C., Vaiopoulos, G., Palermos, J., Yataganas, X., Goldman, J.M., Rahemtulla, A. Eur. J. Haematol. (2003) [Pubmed]
  26. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. Menssen, H.D., Sakalová, A., Fontana, A., Herrmann, Z., Boewer, C., Facon, T., Lichinitser, M.R., Singer, C.R., Euller-Ziegler, L., Wetterwald, M., Fiere, D., Hrubisko, M., Thiel, E., Delmas, P.D. J. Clin. Oncol. (2002) [Pubmed]
  27. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Delmas, P.D., Adami, S., Strugala, C., Stakkestad, J.A., Reginster, J.Y., Felsenberg, D., Christiansen, C., Civitelli, R., Drezner, M.K., Recker, R.R., Bolognese, M., Hughes, C., Masanauskaite, D., Ward, P., Sambrook, P., Reid, D.M. Arthritis Rheum. (2006) [Pubmed]
WikiGenes - Universities